Personalized Medicine in Oncology Partnering Terms and Agreements

Personalized Medicine in Oncology Partnering Terms and Agreements

Regular price $2,995.00 Sale

The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of personalized medicine in oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine in oncology dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in personalized medicine in oncology partnering. The chapter also includes examples case studies of recent deals in personalized medicine in oncology partnering.

Chapter 3 provides a review of the leading personalized medicine in oncology deals since 2007. Deals are listed by headline value signed by all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of personalized medicine in oncology partnering deals signed and announced since January 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in personalized medicine in oncology partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of personalized medicine in oncology technologies and products.

Report Scope

Personalized Medicine in Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine in Oncology Partnering Terms and Agreements includes:

Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2007
Analysis of personalized medicine in oncology deal structure
Case studies of real-life personalized medicine in oncology deals
Access to over 600 personalized medicine in oncology deals
The leading personalized medicine in oncology deals by value since 2007
Most active personalized medicine in oncology dealmakers since 2007
The leading personalized medicine in oncology partnering resources

In Personalized Medicine in Oncology Partnering Terms and Agreements , the available contracts are listed by:

Headline value
Stage of development at signing
Deal component type
Specific therapy target
Specific technology target

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Personalized Medicine in Oncology Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of personalized medicine in oncology deal trends since 2007
Analysis of the structure of personalized medicine in oncology agreements with numerous real life case studies
Comprehensive access to over 600 personalized medicine in oncology deals entered into by the world's biopharma companies
Detailed access to actual personalized medicine in oncology contracts enter into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a personalized medicine in oncology agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Table of Contents

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in personalized medicine in oncology dealmaking
2.1. Introduction
2.2. Personalized medicine in oncology partnering over the years
2.2.1 Biomarker in oncology partnering over the years
2.2.2 Companion diagnostic in oncology partnering over the years
2.2.3 Pharmacogenomics in oncology partnering over the years
2.3. Big pharma personalized medicine in oncology dealmaking activity
2.3.1 Big pharma biomarker, companion diagnostic and pharmacogenomics in oncology dealmaking activity
2.4. Most active in personalized medicine in oncology
2.5. Personalized medicine in oncology partnering by deal type
2.5.1 Biomarker partnering in oncology by deal type
2.5.2 Companion diagnostic in oncology partnering by deal type
2.5.3 Pharmacogenomics in oncology partnering by deal type
2.6. Personalized medicine partnering by oncology disease type
2.6.1 Biomarker partnering by oncology disease type
2.6.2 Companion diagnostic partnering by disease type
2.6.3 Pharmacogenomics partnering by oncology disease type
2.7. Personalized medicine in oncology partnering by stage of development
2.8 Average deal terms for personalized medicine in oncology
2.8.1 Personalized medicine in oncology headline values
2.8.2 Personalized medicine in oncology upfront payments
2.8.3 Personalized medicine milestone payments


Companies Mentioned:

Abbott Japan
Abbott Laboratories
Abraxis BioScience
ACADIA Pharmaceuticals
Acceleron Pharma
Achillion Pharmaceuticals
Adnexus Therapeutics
Adolor
AEterna Zentaris
Affymax
Agensys
Alfacell
Allergan
Ambit Biosciences
Amgen
Amylin Pharmaceuticals
Anacor Pharmaceuticals
Anesiva
Archemix
Ariad Pharmaceuticals
ArQule
Array Biopharma
ARYx Therapeutics
Astellas Pharma
AstraZeneca
Athersys
Atley Pharmaceuticals
Auriga Laboratories
Aventis
AVEO Pharmaceuticals
Barrier Therapeutics
Bayer
Biogen Idec
BioMarin Pharmaceuticals
BioMerieux
Biovail
Boehringer Ingelheim
Bristol-Myers Squibb
Cardiome Pharma
Celgene
Cell Genesys
Cepheid
ChemoCentryx
Cornerstone Biopharma
Cortex Pharmaceuticals
Critical Therapeutics
Cubist Pharmaceuticals
CV Therapeutics
Cypress Bioscience
Cytokinetics
Daiichi Sankyo
DepoMed
Dey Pharma
DoctorDirectory
DOR BioPharma
Dyax
Dynavax Technologies
Eisai
Eli Lilly
Enanta Pharmaceuticals
Endo Pharmaceuticals
Exelixis
Facet Biotechnology
Forest Laboratories
Forest Pharmaceuticals
Galderma
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
GTx
Hyperion Therapeutics
ImmunoGen
Immunomedics
Impax Laboratories
Incyte
Inspire Pharmaceuticals
InterMune
InVentiv Health
Ipsen
Ironwood Pharmaceuticals
Janssen Research & Development
KaloBios Pharmaceuticals
La Jolla Pharmaceutical
Macrogenics
MAP Pharmaceuticals
Maxygen
Medivation
Menarini
Merck and Co
Merck KGaA
Merck Sharpe & Dohme
Merrimack Pharmaceuticals
Metabasis Therapeutics
Micromet
MiddleBrook Pharmaceutical
Millennium
Mylan Laboratories
Nektar Therapeutics
Novartis
Novartis Consumer Health
Novo Nordisk
Nycomed
OncoGenex Pharmaceuticals
Optimer Pharmaceuticals
Orexigen Therapeutics
Ortho Biotech
Par Pharmaceutical
PDL BioPharma
Pfizer
PhotoMedex
Procter & Gamble
Procter & Gamble Pharmaceuticals
Purdue Pharma
Regeneron Pharmaceuticals
Rib-X Pharmaceuticals
Roche
Sagent Pharmaceuticals
Salix Pharmaceuticals
Sanofi-Aventis
Sanofi-Pasteur
Sanofi
Santarus
Schering-Plough
Seattle Genetics
Serono
Sigma-Tau
Solvay
Somaxon Pharmaceuticals
Spectrum Pharmaceuticals
Strativa Pharmaceuticals
Sucampo Pharmaceuticals
Synta Pharmaceuticals
Takeda Pharmaceutical
TAP Pharmaceutical
Targacept
Tercica
Teva Pharmaceuticals
Tibotec
Transcept Pharmaceuticals
Ucyclyd Pharma
Valeant Pharmaceuticals
Veracyte
Vernalis
Vical
Victory Pharma
Warner Chilcott
Watson Pharmaceuticals
Wyeth
Xenoport
Zogenix
ZymoGenetics